Hospital-acquired or nosocomial infections are a major challenge to patient safety. They are the sixth leading cause of death in the United States. A total of 1.7 million hospital-acquired infections occur and approximately 99,000 deaths are associated with hospital-acquired infections. Gram negative bacteria account for greater than 30% of hospital-acquired infections.1 Nosocomial pathogens and multidrug resistance are a potential threat to humans worldwide.2,3 Bacterial strains that are resistant to ≥4 classes of antimicrobials are called multidrug resistant.4 Multidrug resistance contribute not only to major therapeutic stress but also cause significant morbidity and mortality nowadays. Acinetobacter species is an important cause of nosocomial infections worldwide.2,3 The increase in the prevalence of Acinetobacter species is alarming due to narrow therapeutic range attributed to its multidrug resistant pattern.20 A total of 2490 clinical specimens were received in the Pathology laboratory for culture and sensitivity from different departments of the Sharif Medical City Hospital and were processed for isolation & identification and antimicrobial susceptibility testing as recommended by Clinical and Laboratory Standard Institute (CLSI).17 Out of the 2490 culture specimens, 51(2%) positive cultures for Acinetobacter species were obtained. Thirty one percent strains were sensitive and 6% were intermediate to cefoperazone-sulbactam. Most of the isolates were resistant to other antimicrobials. Five (9.8%) strains of Acinetobacter species were resistant to all of the antimicrobials.
Antimicrobial Susceptibility Pattern of Isolated Acinetobacter Species